Neurobiological Technologies News

The research deal between the Emeryville company and Novato institute formally ended Friday.

From the Neurobiological Technologies, Inc , Edgewater, NJ; and the Department of Neurology , University of Virginia, Charlottesville, Va.

From the Neurobiological Technologies, Inc , Edgewater, NJ; and the Department of Neurology , University of Virginia, Charlottesville, Va.

This report is an update to a previous version and is updated to 24th April 2009.

Neurobiological Technologies Inc has engaged a financial adviser to explore a sale of the company or its major assets to determine "if there is a transaction more beneficial to our shareholders than a liquidation," according to its CEO, William Fletcher.

Neurobiological Technologies, Inc. ) announced today that it has hired RBC Capital Markets as its exclusive financial advisor to assist in the evaluation of various options to enhance shareholder value, including a potential sale of the Company or its major assets.

Emeryville-based Neurobiological Technologies Inc. intends to sell itself or its major assets as the biotech company winds down its operations following multiple setbacks.

Gregory J. del Zoppo MD, PhD*; David E. Levy MD; Warren W. Wasiewski MD; Arthur M. Pancioli MD; Andrew M. Demchuk MD; James Trammel MS; Bart M. Demaerschalk MD; Markku Kaste MD, PhD; Gregory W. Albers MD; and Eric B. Ringelstein MD From Harborview Medical Center , University of Washington, Seattle, Wash, USA; i3Statprobe , Stonewall, La, USA; ...

Neurobiological Technologies Inc is a particularly interesting play. Prima facie, it appears to be a cash-burning biotechnology stock trading at a premium to its liquidating value.

Neurobiological Technologies Inc. has appointed William Fletcher as the company's acting chief executive officer, replacing Paul Freiman.

EMERYVILLE, Calif., Feb. 4 CA-NTI-appoints-CEO EMERYVILLE, Calif. , Feb. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. today announced that, following a detailed analysis of the recent interim results of the Viprinex clinical trial, the company has decided not to develop Viprinex further for ...

Main Category: Fertility Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 18 Dec 2008 - 4:00 PST Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. ) today announced that Celtic Pharmaceutical Holdings L.P. has provided an update on XERECEPT .

Neurobiological Technologies Inc. said its stroke treatment derived from the venom of the Malayan pit viper did not pass an early analysis of Phase III trial data, and the Emeryville company said it may face ...